PDCD1 and glioblastoma: Finally, in GBM patients receiving anti‐PD‐1 therapy,27 the AUCs of our riskscore in predicting overall survival from anti‐PD‐1 therapy was better (Figure 7H) compared to the T‐cell‐inflamed signature (TIS, Figure 7I)28 and the TIDE score (Figure 7J) at 6‐, 12‐, and 18‐month follow‐up point.